Tranexamic Acid reduces blood loss and blood product use during pediatric cranial vault remodeling

Abstract

RESULTS: A total of 210 patients were identified, 47 were treated with TXA. No difference in preoperative characteristics between groups was identified; average age at time of surgery was 9 months. Estimated blood loss was significantly reduced in the TXA group (33.4 vs 40.6 ml/kg p<0.01), as was red cell transfusion volume (38.8 vs 46.1 ml/kg p<0.01). In the TXA group the need for plasma/cryoprecipitate transfusion was reduced (4% vs 35% p<0.01). No significant difference in vasopressor use was found (6% vs 6% p1⁄40.97). TXA treated patients exhibited higher postoperative hematocrits (33.0 vs 30.9 p<0.01), and decreased drain output (173 vs 344 ml p<0.01). No differences in mortality, length of stay, or post-operative complications were seen between groups.